Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells

被引:97
作者
Taipale, Mikko [1 ]
Krykbaeva, Irina [1 ]
Whitesell, Luke [1 ]
Santagata, Sandro [1 ,2 ,3 ]
Zhang, Jianming [4 ,5 ]
Liu, Qingsong [4 ,5 ]
Gray, Nathanael S. [4 ,5 ]
Lindquist, Susan [1 ,6 ,7 ]
机构
[1] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA
[2] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
[5] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA
[6] MIT, Dept Biol, Cambridge, MA USA
[7] Howard Hughes Med Inst, Cambridge, MA USA
基金
美国国家卫生研究院;
关键词
ACUTE MYELOID-LEUKEMIA; PROTEIN-TYROSINE KINASE; BCR-ABL; INFANTILE FIBROSARCOMA; QUANTITATIVE-ANALYSIS; PONATINIB AP24534; MAMMALIAN-CELLS; INTERACTION MAP; BINDING-SITE; RECEPTOR;
D O I
10.1038/nbt.2620
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The interaction between the HSP90 chaperone and its client kinases is sensitive to the conformational status of the kinase, and stabilization of the kinase fold by small molecules strongly decreases chaperone interaction. Here we exploit this observation and assay small-molecule binding to kinases in living cells, using chaperones as 'thermodynamic sensors'. The method allows determination of target specificities of both ATP-competitive and allosteric inhibitors in the kinases' native cellular context in high throughput. We profile target specificities of 30 diverse kinase inhibitors against >300 kinases. Demonstrating the value of the assay, we identify ETV6-NTRK3 as a target of the FDA-approved drug crizotinib (Xalkori). Crizotinib inhibits proliferation of ETV6-NTRK3-dependent tumor cells with nanomolar potency and induces the regression of established tumor xenografts in mice. Finally, we show that our approach is applicable to other chaperone and target classes by assaying HSP70/steroid hormone receptor and CDC37/kinase interactions, suggesting that chaperone interactions will have broad application in detecting drug-target interactions in vivo.
引用
收藏
页码:630 / U90
页数:9
相关论文
共 46 条
  • [11] Comprehensive analysis of kinase inhibitor selectivity
    Davis, Mindy I.
    Hunt, Jeremy P.
    Herrgard, Sanna
    Ciceri, Pietro
    Wodicka, Lisa M.
    Pallares, Gabriel
    Hocker, Michael
    Treiber, Daniel K.
    Zarrinkar, Patrick P.
    [J]. NATURE BIOTECHNOLOGY, 2011, 29 (11) : 1046 - U124
  • [12] The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl
    Eck, Michael J.
    Manley, Paul W.
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2009, 21 (02) : 288 - 295
  • [13] Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25)
    Eguchi, M
    Eguchi-Ishimae, M
    Tojo, A
    Morishita, K
    Suzuki, K
    Sato, Y
    Kudoh, S
    Tanaka, K
    Setoyama, M
    Nagamura, F
    Asano, S
    Kamada, N
    [J]. BLOOD, 1999, 93 (04) : 1355 - 1363
  • [14] A small molecule-kinase interaction map for clinical kinase inhibitors
    Fabian, MA
    Biggs, WH
    Treiber, DK
    Atteridge, CE
    Azimioara, MD
    Benedetti, MG
    Carter, TA
    Ciceri, P
    Edeen, PT
    Floyd, M
    Ford, JM
    Galvin, M
    Gerlach, JL
    Grotzfeld, RM
    Herrgard, S
    Insko, DE
    Insko, MA
    Lai, AG
    Lélias, JM
    Mehta, SA
    Milanov, ZV
    Velasco, AM
    Wodicka, LM
    Patel, HK
    Zarrinkar, PP
    Lockhart, DJ
    [J]. NATURE BIOTECHNOLOGY, 2005, 23 (03) : 329 - 336
  • [15] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases
    Fedorov, Oleg
    Marsden, Brian
    Pogacic, Vanda
    Rellos, Peter
    Mueller, Susanne
    Bullock, Alex N.
    Schwaller, Juerg
    Sundstrom, Michael
    Knapp, Stefan
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (51) : 20523 - 20528
  • [16] Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children's Oncology Group study
    Gadd, Samantha
    Beezhold, Patricia
    Jennings, Lawrence
    George, David
    Leuer, Katrin
    Huang, Chiang-Ching
    Huff, Vicki
    Tognon, Cristina
    Sorensen, Poul H. B.
    Triche, Timothy
    Coffin, Cheryl M.
    Perlman, Elizabeth J.
    [J]. JOURNAL OF PATHOLOGY, 2012, 228 (01) : 119 - 130
  • [17] Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
    Galkin, Anna V.
    Melnick, Jonathan S.
    Kim, Sungjoon
    Hood, Tami L.
    Li, Nanxin
    Li, Lintong
    Xia, Gang
    Steensma, Ruo
    Chopiuk, Greg
    Jiang, Jiqing
    Wan, Yongqin
    Ding, Peter
    Liu, Yi
    Sun, Fangxian
    Schultz, Peter G.
    Gray, Nathanael S.
    Warmuth, Markus
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (01) : 270 - 275
  • [18] High-throughput kinase profiling as a platform for drug discovery
    Goldstein, David M.
    Gray, Nathanael S.
    Zarrinkar, Patrick P.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (05) : 391 - 397
  • [19] An atlas of chaperone-protein interactions in Saccharomyces cerevisiae: implications to protein folding pathways in the cell
    Gong, Yunchen
    Kakihara, Yoshito
    Krogan, Nevan
    Greenblatt, Jack
    Emili, Andrew
    Zhang, Zhaolei
    Houry, Walid A.
    [J]. MOLECULAR SYSTEMS BIOLOGY, 2009, 5
  • [20] Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
    Gozgit, Joseph M.
    Wong, Matthew J.
    Moran, Lauren
    Wardwell, Scott
    Mohemmad, Qurish K.
    Narasimhan, Narayana I.
    Shakespeare, William C.
    Wang, Frank
    Clackson, Tim
    Rivera, Victor M.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2012, 11 (03) : 690 - 699